Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives
Information source: Abbott
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Obesity; Hypertension
Intervention: sibutramine (Drug); sibutramine (Drug); verapamil/trandolapril (Drug); metoprolol/HCT (Drug); felodipine/ramipril (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Abbott
Summary
To study the effect of sibutramine treatment on weight reduction and blood pressure
improvement in three groups with antihypertensive therapy whose blood pressure was not
adequately controlled with antihypertensive combination treatment.
Clinical Details
Official title: Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment
Primary outcome: Systolic Blood PressureDiastolic Blood Pressure
Eligibility
Minimum age: 20 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Treated essential hypertension.
- Obesity: BMI 27-35 kg/m2
Exclusion Criteria:
- Secondary hypertension.
- Stage 3 hypertension.
- Secondary obesity; BMI > 35kg/m2.
- CAD; MI within past 6 months; NYHA stage 3 or 4 heart failure; tachyarrhythmia/atrial
fibrillation; myocarditis.
- Kidney failure.
- Liver failure.
- Hyperthyroidism.
- Unstable DM.
- Carcinoma.
- Severe chronic infectious disease.
- Alcohol or drug abuse.
- Pregnancy.
- Epilepsy.
- Psychosis or treatment with antidepressants or major tranquilizers
Locations and Contacts
Additional Information
Starting date: February 2002
Last updated: May 16, 2008
|
